GENOTECH CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,589 KRW | +7.00% |
|
-0.25% | -16.24% |
| 2018 | Genotech Corp. announced that it has received KRW 399.99753 million in funding | CI |
| 2018 | Genotech Corp. announced that it expects to receive KRW 399.99753 million in funding | CI |
More news
| 1 day | +7.00% | ||
| 1 week | -0.25% | ||
| 1 month | -0.69% | ||
| 3 months | -0.69% | ||
| 6 months | -16.32% | ||
| Current year | -16.24% |
1 week
1 485.00
1 592.00
1 month
1 480.001 790.00
Current year
1 360.002 100.00
1 year
1 360.002 695.00
3 years
1 360.005 100.00
5 years
940.005 100.00
10 years
940.007 430.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Jong Kim
CEO | Chief Executive Officer | 62 | - |
Shi-Kyu Yim
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
Il-Soo Kim
BRD | Director/Board Member | 58 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Il-Soo Kim
BRD | Director/Board Member | 58 | - |
Seung-Woo Baek
BRD | Director/Board Member | 60 | - |
Ju-Hwan Kim
BRD | Director/Board Member | 62 | 21-03-28 |
Genotech Corporation is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company operates its business through three segments. Bio-Phamaceutical segment is involved in the manufacturing and sale of the main ingredients of finished pharmaceuticals such as antibiotics and immunosuppressants. Deoxyribonucleic Acid (DNA) & Ribonucleic Acid (RNA) Synthesis segment is involved in the manufacturing and sale of materials for biotechnology research including gene manipulation, polymerase chain reaction (PCR), cloning, and sequencing. Genome Analysis Service segment is involved in the analysis of the gene sequences of the samples requested by customers and the provision of analysis results.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -16.24% | 6.43M | |
| +41.50% | 739B | |
| +32.40% | 598B | |
| -5.31% | 353B | |
| +17.21% | 318B | |
| +4.67% | 285B | |
| +16.60% | 240B | |
| +9.65% | 210B | |
| -5.15% | 206B | |
| +7.67% | 164B |
- Stock Market
- Equities
- A066830 Stock
